Covered recipient · General Payments record
NICOLE ABBOT
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
General Payments · PY2021–2024
$1,248.65
- Reported across 65 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $356.91 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $216.11 | 12 |
| Lilly USA, LLC | $35.96 | 2 |
| Vanda Pharmaceuticals Inc. | $30.62 | 1 |
| Axsome Therapeutics, Inc. | $29.07 | 1 |
| Teva Pharmaceuticals USA, Inc. | $23.99 | 1 |
| Otsuka America Pharmaceutical, Inc. | $21.16 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $10.27 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162706 | CMS |
| ABBVIE INC. | $13.00 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162708 | CMS |
| ABBVIE INC. | $18.03 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162710 | CMS |
| ABBVIE INC. | $8.60 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162712 | CMS |
| ABBVIE INC. | $26.18 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162714 | CMS |
| ABBVIE INC. | $20.27 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162716 | CMS |
| ABBVIE INC. | $14.15 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162718 | CMS |
| ABBVIE INC. | $31.31 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162720 | CMS |
| ABBVIE INC. | $19.16 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162722 | CMS |
| ABBVIE INC. | $24.01 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162724 | CMS |
| ABBVIE INC. | $10.14 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162726 | CMS |
| ABBVIE INC. | $20.99 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103162728 | CMS |
| Axsome Therapeutics, Inc. | $29.07 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148308622 | CMS |
| Lilly USA, LLC | $18.33 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135234603 | CMS |
| Lilly USA, LLC | $17.63 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135248699 | CMS |
| Otsuka America Pharmaceutical, Inc. | $21.16 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118847076 | CMS |
| Teva Pharmaceuticals USA, Inc. | $23.99 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151545501 | CMS |
| Vanda Pharmaceuticals Inc. | $30.62 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133893879 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.